Co-Diagnostics Signs Agreement to Significantly Expand Commercial and Distribution Territory Across South Asia
MWN-AI** Summary
Co-Diagnostics, Inc. (Nasdaq: CODX) has announced a pivotal expansion of its commercial and distribution territory across South Asia through an agreement with CoSara Diagnostics Pvt. Ltd., its Indian joint venture. This agreement enables CoSara to include Bangladesh, Pakistan, Nepal, and Sri Lanka in its operations, significantly enlarging its addressable market in the region to an estimated $13 billion, based on internal analyses and third-party data.
The expansion aligns with CoSara's commercialization strategy for its CoSara PCR Pro® point-of-care instrument and SARAGENE® product line. To facilitate this strategic move, CoSara will establish distribution channels in the newly included markets, assess regulatory pathways, identify priority customer segments, and engage local distribution partners. This initiative aims to improve access to molecular diagnostics for critical health issues such as tuberculosis, HPV, and upper respiratory infections across South Asia.
CoSara's CEO, Mohal Sarabhai, emphasized the growing demand for non-invasive and reliable testing solutions in South Asia, and expressed enthusiasm about building partnerships in these new territories. Co-Diagnostics' CEO, Dwight Egan, reinforced that this expansion is part of a larger vision to build regional infrastructures that will support the scalable, global deployment of their PCR platform, which is under review for regulatory approval.
Additionally, CoSara plans to conduct a virtual distributor information session in Q2 2026, followed by in-person meetings later in the summer, to further engage with potential distribution partners. The expansion is poised to significantly impact Co-Diagnostics' growth potential in a key market while addressing the urgent healthcare needs of the region.
MWN-AI** Analysis
Co-Diagnostics, Inc. (NASDAQ: CODX) has made a strategic move by partnering with CoSara Diagnostics to significantly expand its commercial and distribution presence in South Asia, which includes key markets like Bangladesh, Pakistan, Nepal, and Sri Lanka. This expansion is a noteworthy development that potentially increases Co-Diagnostics' total addressable market (TAM) in the region to $13 billion.
Investors should view this as an opportunity worth exploring, given the rising demand for molecular diagnostics in these emerging markets. The press release emphasizes the need for reliable and non-invasive testing solutions, especially for conditions such as tuberculosis and HPV, which can have significant public health implications in the region. The expedited commercialization of the CoSara PCR Pro® point-of-care instrument and the SARAGENE® product line will be crucial for meeting this need.
With the South Asian molecular diagnostics market exhibiting rapid growth, Co-Diagnostics is well-positioned to capitalize on this trend. The company’s proactive approach to building local manufacturing and distribution capabilities aligns well with its long-term growth strategy, which seeks to advance healthcare accessibility and improve diagnostic outcomes.
However, investors should remain mindful of several risks intrinsic to this expansion. Regulatory approvals in the various jurisdictions may present hurdles, and the competitive landscape in the molecular diagnostics market is rapidly evolving. Additionally, economic and geopolitical dynamics in South Asia could impact operational efficiency and market acceptance.
As Co-Diagnostics embarks on this expansion journey, they plan to engage regional distributors, which may enhance their market footprint. Investors could consider monitoring upcoming distributor information sessions, as these provide insights into the company’s growth strategy and potential partnership opportunities.
In summary, Co-Diagnostics' expansion in South Asia offers promising prospects; however, prudent assessment of associated risks is advised for prospective investors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Expansion into Bangladesh, Pakistan, Nepal, and Sri Lanka increases TAM in region to $13 billion and supports commercialization strategy for the PCR Pro® and SARAGENE® product line
SALT LAKE CITY, March 20, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company has signed an agreement for CoSara Diagnostics Pvt. Ltd. ("CoSara"), the Indian joint venture between Co-Dx and Ambalal Sarabhai Enterprises Limited ("ASE Group"), to significantly expand its commercial and distribution territory across South Asia to now include Bangladesh, Pakistan, Nepal, and Sri Lanka.
The expansion significantly increases CoSara's addressable market across South Asia, bringing the total regional opportunity to an estimated $13.0 billion based on internal analyses and third-party market data. It also supports CoSara's plans to commercialize the CoSara PCR Pro® point-of-care instrument and tests as well as the SARAGENE® product line across the region, subject to applicable regulatory approvals in each jurisdiction. As part of this expansion, CoSara is working to establish distribution channels in these newly added markets, including evaluating regulatory pathways, identifying priority customer segments, and engaging regional distribution partners.
Mohal Sarabhai, CEO of CoSara, commented, "South Asia represents a large and rapidly growing market for molecular diagnostics, with significant need for easily accessible, non-invasive, quick and reliable testing solutions. Expanding our territory allows us to begin building relationships with regional partners and positions us to support the future commercialization of the point-of-care PCR platform across these markets, increasing access to molecular tests for tuberculosis, HPV, and upper respiratory infections."
Co-Diagnostics CEO Dwight Egan added, "This expansion reflects our broader strategy of establishing regional infrastructure ahead of product commercialization. By building local manufacturing and distribution capabilities in key regions, including the United States, South Asia, and the Middle East and North Africa, we are positioning Co-Dx to support scalable, global deployment of our PCR point-of-care platform and drive long-term growth."
To support these efforts, CoSara plans to host a virtual distributor information session in Q2 2026, followed by an in-person distributor meeting and training event later this summer. Distributors interested in participating may contact the Company at info@co-dx.com for more information.
*The Co-Dx PCR platform (including the PCR Home®, PCR Pro®, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will," "seeks," "anticipates," and similar expressions, or the negative of these terms. Forward-looking statements in this press release include, but are not limited to, statements regarding: the expected benefits of CoSara's expansion into additional South Asian markets, including the size and potential of the addressable market; plans to establish and develop distribution channels and partnerships in newly added territories; the timing, scope, and success of commercialization efforts for the Co-Dx PCR Pro® instrument, SARAGENE® product line, and related tests; anticipated regulatory pathways, submissions, approvals, and requirements in India and other jurisdictions; the Company's ability to build regional manufacturing and distribution infrastructure; planned distributor engagement activities and their expected outcomes; and the Company's broader strategy for global deployment and adoption of its PCR platform. These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management as of the date of this release. Such statements are subject to a number of risks and uncertainties, including, without limitation: risks related to the Company's ability to obtain necessary regulatory approvals in multiple jurisdictions; uncertainties associated with market acceptance and adoption of the Company's products; the ability to successfully establish and manage distribution relationships; competitive dynamics in the global molecular diagnostics market; execution risks associated with international expansion; and general economic, geopolitical, and public health conditions in the regions in which the Company operates or intends to operate. Actual results may differ materially from those expressed or implied in these forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. A further description of risks and uncertainties can be found in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 27, 2025, and in its other filings with the SEC. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.
SOURCE Co-Diagnostics
FAQ**
How will Co-Diagnostics Inc. CODX leverage the $billion total addressable market opportunity in South Asia to enhance its position in the molecular diagnostics sector?
What specific regulatory challenges does Co-Diagnostics Inc. CODX anticipate in commercializing the PCR Pro® and SARAGENE® product lines in Bangladesh, Pakistan, Nepal, and Sri Lanka?
In what ways does Co-Diagnostics Inc. CODX plan to establish effective distribution channels and partnerships in these newly added South Asian markets?
How does the expansion into South Asia align with Co-Diagnostics Inc. CODX's broader strategy for global deployment and scalability of its molecular diagnostic technology?
**MWN-AI FAQ is based on asking OpenAI questions about Co-Diagnostics Inc. (NASDAQ: CODX).
NASDAQ: CODX
CODX Trading
46.03% G/L:
$2.015 Last:
98,317,390 Volume:
$1.95 Open:
